ArticleOncotarget2014
CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review.Cancer science · 2016Pooled it
- Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor.Frontiers in oncology · 2026Article
- Differential contribution of TFE3 isoforms to cell motility and invasion.EMBO reports · 2026Article
- Exploring the role of CITED transcriptional regulators in the control of macrophage polarization.Frontiers in immunology · 2024Review
- Roles and signaling pathways of CITED1 in tumors: overview and novel insights.The Journal of international medical research · 2024Review
- Identification and Characterization of the Wilms Tumor Cancer Stem Cell.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Increased soluble E‑cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells.Oncology letters · 2023Article
- Exploiting embryonic niche conditions to grow Wilms tumor blastema in culture.Frontiers in oncology · 2023Article
- Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.Cancer discovery · 2021Article
- MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children.Journal of clinical laboratory analysis · 2019Article
- FXR1 expression domain in Wilms tumor.Journal of pediatric surgery · 2019Article
- CITED1 contributes to the progression of papillary thyroid carcinoma via the Wnt/β-catenin signaling pathway.OncoTargets and therapy · 2019Article
- Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.World journal of pediatrics : WJP · 2018Article
- knnAUC: an open-source R package for detecting nonlinear dependence between one continuous variable and one binary variable.BMC bioinformatics · 2018Article
- Effect of Hypoxia on the Differentiation and the Self-Renewal of Metanephrogenic Mesenchymal Stem Cells.Stem cells international · 2017Article
- TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.Current biology : CB · 2015Article
- Genetic and chromosomal alterations in Kenyan Wilms Tumor.Genes, chromosomes & cancer · 2015Article
- SIX2 Effects on Wilms Tumor Biology.Translational oncology · 2014Article
- The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.Oncotarget · 2014Article
- SNU-333 Cells as an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Wilms tumor (WT) is the most common childhood kidney cancer and retains gene expression profiles reminiscent of the embryonic kidney. We have shown previously that CITED1, a transcriptional regulator that labels the self-renewing, multipotent nephron progenitor population of the developing kidney, is robustly expressed across all major WT disease and patient characteristics. In this malignant context, CITED1 becomes enriched in the nucleus, which deviates from its cytosolic predominance in embryonic nephron progenitors. We designed the current studies to test the functional and mechanistic effects of differential CITED1 subcellular localization on WT behavior. To mimic its subcellular distribution observed in clinical WT specimens, CITED1 was misexpressed ectopically in the human WT cell line, WiT49, as either a wild-type (predominantly cytosolic) or a mutant, but transcriptionally active, protein (two point mutations in its nuclear export signal, CITED1ΔNES; nuclear-enriched). In vitro analyses showed that CITED1ΔNES enhanced WiT49 proliferation and colony formation in soft agar relative to wild-type CITED1 and empty vector controls. The nuclear-enriched CITED1ΔNES cell line showed the greatest tumor volumes after xenotransplantation into immunodeficient mice (n=15 animals per cell line). To elucidate CITED1 gene targets in this model, microarray profiling showed that wild-type CITED1 foremost upregulated LGR5 (stem cell marker), repressed CDH6 (early marker of epithelial commitment of nephron progenitors), and altered expression of specific WNT pathway participants. In summary, forced nuclear enrichment of CITED1 in a human WT cell line appears to enhance tumorigenicity, whereas ectopic cytosolic expression confers stem-like properties and an embryonic phenotype, analogous to the developmental context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.